Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Momentum forward

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Nov 25, 2022 6:37pm

215 Views

Post# 35129322

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Momentum forward

Not a game Norm and why is it a suspicious question to ask for the quotes in regards to the 3-4 analysts that all say we will have a partnership early 2023.

I will give you an example from what I post as this is a quote from the latest Leed Jones Report.
Accordingly, we expect Oncolytics to be a partnered Phase III-stage oncology biologics developer no later than FH124."

All I was looking for was the quotes that said partnership 2023, as I do not have access to the Wainwright report for example and sometimes people are kind enough to provide a link to those reports.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles